PER® New York Lung Cancer Symposium | Conference

Chemoimmunotherapy Remains Best Choice for Some PD-L1–High Lung Cancers

November 10th 2020

November 10, 2020 - Nasser Hanna, MD, discusses immunotherapy and, although, it may be the right therapy for most patients with lung cancer expressing PD-L1 greater than or equal to 50%, for those who are at risk for cancer-related morbidity with early progressive disease, chemoimmunotherapy may be the more appropriate choice.

MET, RET, and TRK Inhibitors Achieve Standard-of-Care Status in Lung Cancer

November 9th 2020

Alterations in MET, RET, and NTRK have become established actionable drivers of oncogenesis in lung cancer, and therapeutics targeting these aberrations have since obtained regulatory approval from the FDA and have been incorporated into treatment guidelines.

KRAS G12C Emerges as an Actionable Alteration in NSCLC

November 9th 2020

Although historically considered to be undruggable, the KRAS G12C mutation has since emerged as an actionable alteration in the field of non–small cell lung cancer.

ctDNA Shows Promise as a Potential Biomarker for MRD in Locally Advanced NSCLC

November 9th 2020

Maximilian Diehn, MD, PhD, discusses how the use of circulating tumor DNA to analyze minimal residual disease status in patients with lung cancer and other solid tumors is a rapidly developing field with the potential to further personalize treatment decisions about adjuvant therapy.

Halmos Highlights Lessons Learned From the COVID-19 Crisis in Lung Cancer

November 9th 2020

The oncology community has risen up as a unified front in the battle against coronavirus disease 2019, launching pivotal research efforts to better understand the enemy and collecting data to develop effective therapeutics to fill the treatment arsenal.

TMB Shows Potential as Immunotherapy Biomarker in Lung Cancer, But Challenges Remain

November 7th 2020

Tumor mutational burden has been associated with response to immunotherapy in patients with lung cancer, but there have been various criticisms regarding the validity and routine use of this as a biomarker.

Management of Small Cell Lung Cancer Moves Forward With Immunotherapy

November 7th 2020

Frontline chemoimmunotherapy trials represent a critical milestone in extensive-stage small cell lung cancer, but one that requires better understanding of the methods that can be used to broaden the patient population in whom durable benefit is currently concentrated.

Efforts to Target Actionable Alterations in Lung Cancer Abound, Emphasizing Need for Testing

November 7th 2020

Tony S. K. Mok, MD, BMSc, FRCPC, FASCO, discusses the actionable mutations that have been identified in the lung cancer space, the agents that have been developed to target them, and the importance of genetic testing to provide personalized care.

Dr. Rohs on the Importance of Genetic Testing in NSCLC

November 7th 2020

Nicholas C. Rohs, MD, discusses the importance of genetic testing in non–small cell lung cancer.

Dr. Rizk on the Evolution of Surgery in Lung Cancer

November 7th 2020

Nabil P. Rizk, MD, MS, MPH, discusses the evolving role of surgery in lung cancer.

Dr. Owonikoko on Standard of Care for SCLC

November 15th 2019

Taofeek K. Owonikoko, MD, PhD, discusses current standard of care treatments for patients with small cell lung cancer.

Dr. Kelly on Determining Second-Line TKI in Lung Cancer

November 14th 2019

Karen Kelly, MD, discusses how to determine treatment after patients with lung cancer progress on TKIs.

NGS Testing Is Essential Before Induction in NSCLC

November 12th 2019

Suresh S. Ramalingam, MD, FASCO, highlights current and emerging therapies for 6 key actionable driver mutations in non–small cell lung cancer.

Dr. Borghaei on the Search for Biomarkers in Lung Cancer

November 12th 2019

Hossein Borghaei, DO, MS, discusses the search for biomarkers in lung cancer.

Dr. Halmos on Actionable Biomarkers in NSCLC

November 12th 2019

Balazs Halmos, MD, MS, discusses actionable biomarkers in patients with oncogene-driven non–small cell lung cancer.

Dr. Hirsch on the Expansion of Molecular Testing in Lung Cancer

November 12th 2019

Fred R. Hirsch, MD, PhD, discusses the expansion of molecular testing in lung cancer.

Plasma NGS Demonstrating Practice-Changing Potential in NSCLC

November 12th 2019

Plasma genotyping is the next big thing in non–small cell lung cancer, and it's already impacting clinical practice.

Osimertinib Positioned as Preferred Frontline Treatment for EGFR-Mutant NSCLC

November 12th 2019

Zofia Piotrowska, MD, MHS, discusses the role of osimertinib in treating patients with EGFR-mutant non–small cell lung cancer and how it compares with other therapeutic options in that space.

Dr. Ramalingam on FLAURA Trial Results in EGFR-Mutant NSCLC

November 10th 2019

Suresh S. Ramalingam, MD, FASCO, discusses updated data from the FLAURA trial in EGFR-mutant non–small cell lung cancer.

Dr. Hanna on Challenges With Consolidation Immunotherapy in Lung Cancer

November 10th 2019

Nasser H. Hanna, MD, discusses challenges in consolation immunotherapy for patients with lung cancer.